iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.8246
+0.0204 (2.54%)
Oct 29, 2026, 11:16 AM EDT - Market open
iBio, Inc. Revenue
In the fiscal year ending June 30, 2026, iBio, Inc. had annual revenue of $100.00K, down -75.00%. That makes iBio, Inc. the 46,053rd largest company in the world by revenue and 6,789th in the United States.
Revenue (ttm)
$100.00K
Revenue Growth
-75.00%
P/S Ratio
517.16
Revenue / Employee
$4,348
Employees
23
Market Cap
53.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 100.00K | -300.00K | -75.00% |
| Jun 30, 2025 | 400.00K | 175.00K | 77.78% |
| Jun 30, 2024 | 225.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | 1.64M | -380.00K | -18.83% |
| Jun 30, 2019 | 2.02M | 1.57M | 354.50% |
| Jun 30, 2018 | 444.00K | 50.00K | 12.69% |
| Jun 30, 2017 | 394.00K | -554.00K | -58.44% |
| Jun 30, 2016 | 948.00K | -903.00K | -48.78% |
| Jun 30, 2015 | 1.85M | 1.65M | 802.93% |
| Jun 30, 2014 | 205.00K | -802.00K | -79.64% |
| Jun 30, 2013 | 1.01M | -270.00K | -21.14% |
| Jun 30, 2012 | 1.28M | 756.92K | 145.54% |
| Jun 30, 2011 | 520.08K | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | 1.18M | 189.55K | 19.20% |
| Jun 30, 2008 | 987.06K | 90.79K | 10.13% |
| Jun 30, 2007 | 896.27K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| Werewolf Therapeutics | 21.00M |
| Caribou Biosciences | 10.04M |
| Connect Biopharma Holdings | 2.95M |
| Hyperion DeFi | 1.40M |
| Mereo BioPharma Group | 500.00K |
IBIO News
- 16 days ago - iBio presents IBIO-610 data from obese non-human primate study - TheFly
- 16 days ago - iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy - GlobeNewsWire
- 6 weeks ago - iBio initiated with a Buy at H.C. Wainwright - TheFly
- 7 weeks ago - iBio, Inc. Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 7 weeks ago - iBio, Inc. Proxy statement: Proxy filing - Filings
- 1 month ago - iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - iBio, Inc. Annual report: Q4 2026 - Filings